Women's Health Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Women's Health Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Cancer Therapy
Combination sorafenib and gemcitabine stabilizes disease in advanced solid tumors
March 9th, 2006
A regimen combining sorafenib and gemcitabine stabilized disease in patients with advanced pancreatic cancer and ovarian cancer. "With its potent inhibitory effects against Raf-1 kinase and vascular endothelial growth factor receptor-2, sorafenib is a novel oral anticancer agent targeting signal transduction and angiogenic pathways. This study is designed to combine sorafenib and gemcitabine due to their compatibility in preclinical models and nonoverlapping clinical toxicities," scientists writing in the journal Clinical Cancer Research report. L.L. Siu and colleagues, University of Toronto wrote, "An initial dose-escalation part of the study...
Source: Women's Health Weekly (2006-03-09)
|
